Literature DB >> 213720

Apoprotein A-I synthesis in normal intestinal mucosa and in Tangier disease.

R M Glickman, P H Green, R S Lees, A Tall.   

Abstract

To determine whether human small intestine synthesizes apoA-I, the major apoprotein of plasma high-density lipoproteins, we used immunofluorescence technics and monospecific antiserums to visualize apoA-I within intestinal epithelial cells from four normal subjects and one patient with Tangier disease. Biopsies from all subjects during fasting showed limited fluorescence. After lipid feeding intracellular apoA-I markedly increased in both normal subjects and the patient. During alimentary lipemia, mean plasma apoA-I levels (milligrams per deciliter) increased in four normal subjects from 161 +/- 12 (+/- S.E.M.) to 180 +/- 15 (P less than 0.05) and in the patient from 1.9 to 6.8. Normal plasma chylomicrons contained apoB, apoE and the C peptides but not apoA-I. The patient's chylomicrons contained ap0A-I. Normal and Tangier-disease intestinal-mucosa cells increase their content of apoA-I during chylomicron formation and subsequently contribute to plasma apoA-I levels. The low levels of apoA-I in Tangier disease are not due to a failure of intestinal synthesis but might be due to abnormal metabolism of chylomicron apoproteins.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 213720     DOI: 10.1056/NEJM197812282992602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; A Arranto; C Ehnholm
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Determination of HDL2 cholesterol by precipitation with dextran sulfate and magnesium chloride: establishing optimal conditions for rat plasma.

Authors:  L Sjoblom; A Eklund
Journal:  Lipids       Date:  1989-06       Impact factor: 1.880

3.  Increased proportion of proapolipoprotein A-I in HDL from patients with liver cirrhosis and hepatitis.

Authors:  T Matsuura; S Koga; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1988-08

4.  Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during the catabolism of chylomicrons in the rat.

Authors:  T G Redgrave; D M Small
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

5.  Isolation and characterization of cDNA clones for human apolipoprotein A-I.

Authors:  J L Breslow; D Ross; J McPherson; H Williams; D Kurnit; A L Nussbaum; S K Karathanasis; V I Zannis
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins.

Authors:  G Schmitz; G Assmann; S C Rall; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Human apolipoprotein A-IV. Intestinal origin and distribution in plasma.

Authors:  P H Green; R M Glickman; J W Riley; E Quinet
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

8.  Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice.

Authors:  Zhiqiang Li; Hui Jiang; Tingbo Ding; Caixia Lou; Hai H Bui; Ming-Shang Kuo; Xian-Cheng Jiang
Journal:  Gastroenterology       Date:  2015-07-27       Impact factor: 22.682

9.  Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

Authors:  Yanhong Guo; Yanbo Fan; Jifeng Zhang; Gwen A Lomberk; Zhou Zhou; Lijie Sun; Angela J Mathison; Minerva T Garcia-Barrio; Ji Zhang; Lixia Zeng; Lei Li; Subramaniam Pennathur; Cristen J Willer; Daniel J Rader; Raul Urrutia; Y Eugene Chen
Journal:  J Clin Invest       Date:  2015-09-14       Impact factor: 14.808

10.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.